

EDUARDO MÉNDEZ, MD, MS

Associate Professor

Department of Otolaryngology-Head and Neck Surgery
University of Washington and

Associate Member

Clinical Research Division, Fred Hutchinson Cancer Research Center

1959 NE Pacific Street, Room BB1165, Box 356515

University of Washington

Seattle, WA 98195-6515

(206) 667-2625 (voicemail)

PERSONAL DATA

Place of Birth: San Juan, Puerto Rico

Date of Birth: July 30, 1972

Citizenship: USA

EDUCATION

1990-1994 B.A. in Molecular Biology, Princeton University.

POSTGRADUATE TRAINING

2006-2010 **Masters** in Epidemiology, University of Washington, Seattle, WA.

2005-2006 **Fellowship**, Advanced Head and Neck Surgical Oncology and Microvascular Reconstruction, University of Washington School of Medicine, Seattle, WA.

1999-2005 **Residency**, Otolaryngology-Head and Neck Surgery, University of Washington School of Medicine, Seattle, WA.

1994-1999 **M.D. Cum Laude**, May 1999, University of Maryland at Baltimore School of Medicine, Baltimore, MD.

FACULTY POSITIONS HELD

2016-present Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109.

2012-present Associate Professor, Department of Otolaryngology-Head and Neck Surgery, University of Washington, Seattle, WA 98195, and VA Puget Sound Health Care Systems, Seattle, WA 98108.

2010-2016 Assistant Member, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109.

2006-2009 Affiliate Investigator, Program in Epidemiology, Public Health Science Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109.

2006-2012 Assistant Professor, Department of Otolaryngology-Head and Neck Surgery, University of Washington, Seattle, WA 98195, and VA Puget Sound Health Care System, Seattle, WA 98108.

2005-2006 Senior Fellow/Acting Instructor, Department of Otolaryngology-Head and Neck Surgery, University of Washington, Seattle, WA 98195.

HOSPITAL POSITIONS HELD

Attending Surgeon, Otolaryngology-Head and Neck Surgery

2005-present University of Washington Hospital and Medical Center
Harborview Medical Center
Children's Hospital and Medical Center
Veteran's Administration Hospital

2009-present Seattle Cancer Care Alliance (SCCA)

2014-present Director, Head & Neck Translational Research Program, Fred Hutchinson Cancer Research Center.

2014-present Co-Director, Head and Neck Cancer Program, University of Washington/Seattle Cancer Care Alliance.

2015-present Deputy Director, Head and Neck, Solid Tumor Translational Research Program, Fred Hutchinson Cancer Center.

HONORS

2013 The Trachy Award, Department of Otolaryngology, University of Washington.
Presented annually to the member of the research faculty who has, in opinion of the resident staff, been most influential to their research development.

2008 HHMI Physician-Scientist Early Career Award.

2006 NIH Loan Repayment Program Award.

2003 AACR Minority Scholar Award in Cancer Research.

2001 AACR Minority Scholar Award in Cancer Research.

1999 Honors in Academic Achievement for Medical Degree - *Cum Laude*, University of MD.

1996 Howard Hughes Medical Institute Research Scholar, Cloister Program.

1995 Exceptional Summer Student Award of the National Institute of Neurological Disorders and Stroke, National Institutes of Health.

BOARD CERTIFICATION

2006 American Board of Otolaryngology

CURRENT LICENSE

2005 State of Washington, License number MD00045064

PROFESSIONAL ORGANIZATIONS

2000-present American Academy of Otolaryngology-Head and Neck Surgery

2007-present American Head and Neck Society

2008-present American Association for Cancer Research

2010-present World Robotic Society

TEACHING RESPONSIBILITIES

2006-present Director, Head and Neck Oncology Module for UW OTO H&NS Residents.

SPECIAL LOCAL RESPONSIBILITIES

2006-present Resident Applicant Review Committee, University of Washington Dept. of OTOHNS.

2009-present Director, Head and Neck Tumor Carcinogenesis Biorepository, University of Washington.

- 2009-present Director, Robotic Surgery, Department of Otolaryngology-Head and Neck Surgery.
- 2010-present Member, Robotic Steering Committee, University of Washington.
- 2011-present Director, Fellowship in Advanced Head and Neck Surgical Oncology and Microvascular Reconstruction.
- 2014-present Ad Hoc Member of the Consortium Scientific Review Committee, Fred Hutchinson Cancer Research Center.
- 2014-present Director-Head & Neck Translational Research Program, Fred Hutchinson Cancer Research Center.
- 2014-present Co-Director, Head and Neck Cancer Program, University of Washington/Seattle Cancer Care Alliance.
- 2015-present Deputy Director, Head and Neck, Solid Tumor Translational Research Program, Fred Hutchinson Cancer Center.

SPECIAL NATIONAL RESPONSIBILITIES

1. Centralized Otolaryngology Research Efforts (CORE), ‘head and neck’ grant review study section
2. American Head and Neck Society, Publications Committee
3. American Head and Neck Society, Research Committee
4. Credentialing Committee, RTOG 1221 and ECOG 3311

EDITORIAL ACTIVITIES

JOURNAL PEER REVIEW ACTIVITIES

1. JAMA – Otolaryngology: Head and Neck Surgery
2. Head and Neck
3. Cancer Research
4. Clinical Cancer Research
5. Oral Oncology
6. Oncogene
7. Nature Biotechnology
8. Nature Medicine
9. PLoS One

EDITORIAL BOARD APPOINTMENTS

1. Oral Oncology
2. Cancer

CONFERENCE ORGANIZER, SESSION CHAIR

1. Northwest Academy of Otolaryngology: Panel on Robotic-Assisted Surgery for the Head and Neck. Winter Dinner. Course Faculty, Seattle, WA. January 6-7, 2012.
2. 1st Pacific Northwest Head, Neck and Thyroid Cancer Symposium. Course Co-Director, Seattle, WA. April 1, 2011.
3. 2nd Annual Pacific Northwest Head, Neck and Thyroid Cancer Symposium. Course Co-Director, Seattle, WA. April 6th, 2012.
4. Third Annual Pacific Northwest Head and Neck Cancer Symposium Update on Head and Neck Skin Cancers. Course Co-Director, Seattle, WA. April 19th, 2013.
5. 4th Annual Pacific Northwest Head & Neck Cancer Symposium: Update on Oral Cancer in the Era of HPV. Course Co-Director, Seattle, WA. April 11, 2014.

6. 6th Annual Pacific Northwest Head & Neck Cancer Symposium: Advances in Reconstruction: Optimizing Form and Function. Course Co-Chair, Seattle, WA. July 15, 2016.
7. AHNS 9th International Conference on Head and Neck Cancer: Technology Transforming Head and Neck Cancer Care. Program Chair, Translational/Basic Science Program, Seattle, WA. July 16-20, 2016.
8. AHNS 9th International Conference on Head and Neck Cancer: Technology Transforming Head and Neck Cancer Care. Course Director: Biomarkers and Signature therapeutics: Integrating into Clinical Practice, Seattle, WA. July 16-20, 2016.

RESEARCH FUNDING

ONGOING RESEARCH SUPPORT

1. INDUS Juno (P.I.: Houghton, M) 01/1/17 - 12/31/18 Effort: 0.60 cal mos
 JUNO THERAPEUTICS \$85,434
Tumor Microenvironment Studies and TIL Therapeutics for HPV + Head and Neck Squamous Cell Carcinoma
 The goal of project is to this obtain tumor-infiltrating lymphocytes (TILs) from HPV+ HNSCC cases for the purpose of engineering a TCR directed against HPV as a novel therapeutic.
Role on Project: Co-Investigator
2. STTR Programmatic (P.I.: Méndez, E.) 1/1/16 - 12/31/19 Effort: 0.24 cal mos
 FHCRC \$1,000,000
Therapeutically Targeting the Cell Cycle in Head and Neck Cancer
 The goal of this project is to determine how defects in cell cycle regulation and repair of DNA damage can be used to develop targeted therapies for HNSCC.
Role on Project: Principal Investigator
3. Bezos Immunotherapy (P.I.: Houghton, A.) 4/1/15-3/31/17 Effort: 0.24 cal mos
 FHCRC-PILOT \$75,000
TIL Therapy for Head and Neck Cancer
 The goal of this project is to show proof of principle that tumor infiltrating lymphocytes can be harvested from head and neck cancer samples and expanded. Studies will be done to assess their function. The study also seeks to compare yields between HPV(+) vs. HPV(-) tumors.
Role on Project: Co-Investigator
4. R01 CA 177635-01A1 (P.I.: Eadie, T.) 4/10/14 - 2/28/19 Effort: 1.20 cal mos
 NCI/NIA \$207,500
Communication Outcomes After Head and Neck Cancer
 This research involves validation of a novel tool, the Communicative Participation Item Bank (CPIB), in HNC survivors. We are striving for outcome measures to demonstrate sensitivity and responsivity to changes over time. The development the CPIB also permits the study of the construct of communicative participation and determination of mediators, which has long-term treatment implications.
Role on Project: Co-Investigator
5. U01 CA 176303-02 (P.I.: Kemp, C.) 4/1/13 - 03/31/17
 NCI
An Integrated Computational and Functional Genomics Discovery Engine for Pre-Clinically Validated Cancer Drug Targets
 The goal of this project is to accelerate the discovery and preclinical validation of novel cancer drug targets, including sensitizers to existing standard of care (SOC) therapies, utilizing a platform that includes high throughput well-based siRNA and drug screening, genetically defined isogenic cell systems, patient derived cancer cell cultures, and patient derived xenografts.
Role on Project: Co-Investigator

Sub-Project: 01 (Project Leader: **Méndez E.**) Effort: 1.2 cal mos
Functional Genomics to Discover Novel Therapeutic Target Discovery in Head and Neck Cancer
\$88,202

The goal of this subproject is to identify novel survival pathways and druggable gene targets in p53 mutant head and neck squamous cell carcinoma (HNSCC) utilizing high-throughput genome-wide siRNA and drug screens from patient-derived primary cultures and patient-derived xenografts.

6. INDUS MK-3475 (P.I.: Chow, L.) 6/1/13 - 05/31/17 Effort: 0.30 cal mos
MERK & CO. **\$429,124**

A Phase IB Multi-Cohort Study of MK-3475 in Subjects with Advanced Solid Tumors

To determine the safety and tolerability of MK-3475 in subjects with PD-L1 positive advanced solid tumors and to evaluate anti-tumor activity of MK-3475 in subjects with PD-L1 positive advanced solid tumors based on RECIST 1.1 assessed by independent radiology review.

Role on Project: Co-Investigator

7. FDN RSG 13 0661 01 TBG (P.I.: **Méndez E.**) 1/1/13 - 12/31/17 Effort: 3.60 cal mos
American Cancer Society **\$720,000**

Integrative Genomics Approach Therapeutic Target Selection in Oral Cancer Metastasis

The purpose of this grant is to identify genes whose expression is associated with abnormal copy number which are unique to metastatic oral squamous cell carcinoma (OSCC). In addition, this study will determine which of these candidate genes have the highest association with OSCC survival and which have the highest effect on cell survival and tumor biology in in vitro models of OSCC metastasis.

Role on Project: Principal Investigator

COMPLETED RESEARCH SUPPORT

1. 5 P30 CA015704 (P.I.: **Méndez E.**) 10/1/14 - 12/31/16 Effort: 0.24 cal mos
NIH/NCI **\$50,000**

Cancer Center Support Grant

Cancer Consortium Funding Opportunity for Early Phase Clinical Trials

A Phase I Clinical Trial of MK-1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin Prior to Surgery in p53 Mutated Squamous Cell Carcinoma of the Head and Neck

The goal of this phase I trial is to evaluate the safety profile and determine a MTD dose of MK-1775 in combination with weekly cisplatin and docetaxel as a neoadjuvant approach in early stage to locally advanced resectable stage 1 to 3 (T1-3, N0-1) SCCHN.

Role on Project: Principal Investigator

2. STTR TE 6694 (P.I.: **Méndez, E.**) 7/1/15 - 12/31/16 **\$100,000**

Integration of a prognostic gene signature and UW OncoPlex test to define the mutational landscape of head and neck cancer (HNC) with poor survival

The goal of this project is to develop actionable biomarkers for diagnosis and prognostication of Head and neck cancer.

Role on Project: Principal Investigator

3. STTR TE 6659 (P.I.: **Méndez E.**) 7/1/14 - 6/30/15 **\$45,000**

A Human/Mouse Co-Clinical Trial to Study Response to Small Molecule Inhibitors of G2/M Cell Cycle Regulation in p53-Mutant Head and Neck Cancer

The goal of this 1 year pilot grant is to establish PDX models of head and neck cancer as a useful adjunct in informing AZD1775 treatment effects in clinical trials.

Role on Project: Principal Investigator

4. Howard Hughes MI Grant (P.I.: **Méndez E.**) 8/1/08 - 7/31/14 **\$375,000**

HHMI Physician-Scientist Early Career Award

The purpose of this award is to provide early career support to selected HHMI medical, dental, and veterinary student research training program alumni. This support is intended to foster the ability of the supported scientists to obtain grant support from other organizations.

Role on Project: Principal Investigator

5. 5 P30 CA015704 (PI: Corey, C.) 9/1/11 - 8/31/12
NIH/NCI **\$100,000**
Cancer Center Support Grant Pilot Project
Preclinical Validation of Survival Kinases as Head and Neck Squamous Cell Carcinoma Drug Targets
Major Goals: The purpose of this award is to characterize and validate in a preclinical setting, at least three kinases involved in the PI3/AKT and FAK signaling pathways we found to be required for survival of p53 mutant HNSCC cells and establish a basic mechanism of action.
Role on Project: Principal Investigator
6. R01 CA095419 (PI: Chen, C.) 6/1/03 - 8/31/09
NIH/NCI **\$2,510,332**
Oral Cancer: Molecular Profiles and Clinical Outcomes
The purpose of this project is to determine whether there are specific gene expression profiles that are associated with tumor characteristics and clinical outcomes of oral squamous cell carcinomas.
Role on Project: Co-Investigator, Clinical Lead and Subaward Principal Investigator
7. Robert Wood Johnson Fnd (P.I.: Méndez E.) 7/1/06 - 6/30/10
Harold Amos Medical Faculty Development Award **\$375,000**
Differential Genetic Expression in Metastatic Oral Squamous Cell Carcinoma.
The purpose of this award is to determine the differentially expressed genes in metastatic oral squamous carcinoma cells found in cervical lymph nodes and to develop predictive models of metastasis & survival based on a metastatic expression signature.
Role on Project: Principal Investigator
8. K-12 HD049100-01 (P.I.: Méndez E.) 9/23/06 - 7/31/11
NIH/NCI **\$634,400**
Roadmap K-12 Multidisciplinary Clinical Research Career Development Program
The purpose of this grant is to develop a new generation of scientists in all 6 health science schools at the University of Washington who will pursue clinical research. I am a one of the scholars selected for this 5 year award.
Role on Project: Principal Investigator
9. ITHS Translational Award (P.I.: Méndez E.) 7/1/08 - 6/30/09
University of Washington **\$13,000**
Integration of genomic & transcriptomic changes in metastatic oral squamous cell carcinoma.
Role on Project: Principal Investigator
10. 2R01CA095419-06A1 (PI: Chen, C.) 9/1/09 - 8/31/11
NIH/NCI **\$1,943,911**
Oral Cancer: Molecular Profiles and Clinical Outcomes
The purpose of this competing renewal is to validate various biomarkers that we have previously found to be associated with tumor characteristics and clinical outcomes of oral squamous cell carcinomas in our previous RO1 application.
Role on Project: Co-Investigator, Clinical Lead and Subaward Principal Investigator
11. DC00018 (PI: Weymuller, E.) 7/1/00 - 06/31/01
Research Training in Otolaryngology
NRSA Institutional Training Grant (T32)
Role: Post-Doctoral Fellow
12. HHMI Research Award (P.I.: Méndez E.) 1997 - 1999
Howard Hughes Medical Institute **\$60,000**

The purpose of this award is to provide financial assistance to HHMI Research Scholars in their continuing medical education.

Role on Project: Principal Investigator

CLINICAL TRIAL LEADERSHIP

1. A Phase I clinical trial of AZD1775 in combination with neoadjuvant weekly docetaxel and cisplatin prior to surgery in squamous cell carcinoma of the head and neck (HNSCC). Role: Principal Investigator. Activation July 2015. Sponsor: Astra Zeneca.
2. Phase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer. Role: Institutional Investigator. Activation March 2014. Sponsor: NIH/U10 CA180828.

BIBLIOGRAPHY

1. Méndez E, Kawanishi T, Clemens K, Siomi H, Soldan S, Calabresi P, Brady J, Jacobson S. Astrocyte-specific expression of human T-cell lymphotropic virus type I (HTLV-1) tax: induction of tumor necrosis factor alpha and susceptibility to lysis by CD8+ HTLV-1-specific cytotoxic T-cells. *Journal of Virology*. 1997;71:9143-49.
2. Méndez E, Cheng C, Farwell G, Agoff SN, Futran N, Weymuller EA, Jr., Maronian N, Zhao LP, Chen C. Transcriptional expression profiles of oral squamous cell carcinomas. *Cancer*. 2002;95:1482-94.
3. Kuo WP, Méndez E, Chen C, Whipple M, Farwell G, Agoff N, Park PJ. Functional relationships between gene pairs in oral squamous cell carcinoma. *Annual Symposium Proceedings/AMIA Symposium*. 2003:371-5.
4. Whipple ME, Méndez E, Farwell DG, Agoff SN, Chen C. A genomic predictor of oral squamous cell carcinoma using principal component analysis. *Laryngoscope*. 2004;4(8):1346-54.
5. Whipple ME, Méndez E, Farwell DG, Agoff SN, Chen C. A log likelihood predictor for genomic classification of oral cancer using principle component analysis for feature selection. *Studies in Health Technology and Informatics*. 2004;107(Pt. 2):823-26.
6. Futran ND, Méndez E. Developments in reconstruction of mid-face and maxilla. *Lancet Oncology*. 2006;7(3):249-58.
7. Méndez, E. The incidence of oral cancer appears to be increasing in the United Kingdom. Comment on *Oral Oncol*. Jul 2006;42(6):586-92. Incidence of oral and oropharyngeal cancer in United Kingdom (1990-1999) - Recent trends and regional variation. *Journal of Evidence Based Dentistry*. 2007;(4)182-4.
8. Méndez E, Fan W, Choi P, Agoff SN, Whipple M, Farwell DG, Futran N, Weymuller E, Zhao L, Chen C. Tumor-specific genetic expression profiles of metastatic oral squamous cell carcinoma. *Head & Neck*. 2007;29(9):803-14.
9. Xu C, Houck JR, Fan W, Wang P, Chen Y, Upton M, Futran ND, Schwartz SM, Zhao LP, Chen C, Méndez E. Simultaneous isolation of DNA and RNA from the same cell population obtained by laser capture microdissection for genome and transcriptome profiling. *Journal of Molecular Diagnostics*. 2008;10(2):129-34. PMID: PMC2259466.
10. Choi P, Jordan CD, Méndez E, Houck J, Yueh B, Farwell DG, Futran N, Chen C. Examination of oral cancer biomarkers by tissue microarray analysis. *Archives of Otolaryngology-Head and Neck Surgery*. May 2008;134(5):539-46. PMID: PMC2578846.
11. Chen C, Méndez E, Houck JR, Fan W, Lohavanichbutr P, Yueh B, Futran ND, Upton MP, Farwell DG, Schwartz SM, Zhao LP. Gene expression profiling identifies genes predictive of oral squamous cell carcinoma. *Cancer Epidemiology, Biomarkers & Prevention*. Aug 2008;17(8):2152-62. PMID: PMC2575803.
12. Lohavanichbutr P, Houck J, Fan W, Yueh B, Méndez E, Futran N, Doody DR, Upton MP, Farwell DG, Schwartz SM, Zhao LP, Chen C. Genome-wide gene expression profiles of HPV-positive and HPV-negative oropharyngeal cancer: potential implications for treatment choices. *Archives of Otolaryngology-Head and Neck Surgery*. Feb 2009;135(2):180-8. PMID: PMC2761829.

13. Méndez E, Houck J, Doody DR, Fan W, Lohavanichbutr P, Yueh B, Futran ND, Upton MP, Farwell DG, Schwartz SM, Zhao L, Chen C. A genetic expression profile associated with oral cancer identifies a group of patients at high-risk of poor survival. *Clinical Cancer Research*. Feb 2009;15(4):1353-61. PMID: PMC2683360.
14. Xu C, Liu Y, Wang P, Fan W, Rue TC, Houck JR, Upton M, Futran ND, Zhao LP, Schwartz SM, Chen C, Méndez E. Integrative analysis of DNA copy number and gene expression in metastatic oral squamous cell carcinoma identifies genes associated with poor survival. *Molecular Cancer*. Jun 2010;9:143. PMID: PMC2893102.
15. Méndez E, Lohavanichbutr P, Fan W, Houck JR, Rue TC, Doody DR, Futran ND, Upton MP, Yueh B, Zhao LP, Schwartz SM, Chen C. Can a metastasis gene expression profile outperform tumor size as a predictor of occult lymph node metastasis in oral cancer patients? *Clinical Cancer Research*. April 2011;17(8):2466-73. PMID: PMC3078996.
16. O'Connell D, Teng M, Méndez E, Futran ND. Microvascular free tissue transfer in the reconstruction of scalp and lateral temporal bone defects. *Journal of Craniomaxillofacial Trauma & Reconstruction*. Dec 2011;4(4):179-88. PMID: PMC3314257.
17. Scott-Miller M, Houck J, Lohavanichbutr P, Méndez E, Upton MP, Futran ND, Schwartz SM, Chen C. Tumor and salivary matrix metalloproteinase levels are strong diagnostic markers of oral squamous cell carcinoma. *Cancer Epidemiology Biomarkers & Prevention*. Dec 2011;20(12):2628-36. PMID: PMC3237810.
18. Serrano NA, Nolst-Trenite G, Yueh B, Farwell DG, Futran ND, Méndez E. Risk factors associated with repair of orbital and lateral skull defects. *Archives of Facial Plastic Surgery*. Mar 2012;14(2):97-3. PMID: 22183060. In Press
19. Sharma A, Méndez E, Doody D, Houck J, Lohavanichbutr P, Futran ND, Yueh B, Schwartz SM, Chen C. HPV+ oral cancer patients do not have better QOL trajectory. *Otolaryngology-Head and Neck Surgery*. May 2012;146(5):739-45. PMID: PMC3535430
20. Harrington AT, Hsia JC, Méndez E, Clarridge JE. A lingual abscess caused by streptococcus intermedius. *Journal of Medical Microbiology*. 2012;61:1-3. PMID: 22116986. In Press.
21. Serrano NA, Xu C, Liu Y, Wang P, Fan W, Upton MP, Houck JR, Lohavanichbutr P, Kao M, Zhao LP, Schwartz SM, Chen C, Méndez E. Integrative analysis in oral squamous cell carcinoma reveals DNA copy number-associated miRNAs dysregulating target genes. *Otolaryngology-Head and Neck Surgery*. 2012;147(3):501-08. PMID: 22470160.
22. Méndez E. Biomarkers of HPV infection in oropharyngeal carcinomas: Can we find simplicity in the puzzle of complexity? *Cancer Research*. 2012;72:4896-98. PMID: 22991303. In Press.
23. Lohavanichbutr P, Houck J, Doody DR, Wang P, Méndez E, Futran N, Upton MP, Holsinger FC, Schwartz SM, Chen C. Gene expression in uninvolved oral mucosa of OSCC patients facilitates identification of markers predictive of OSCC outcomes. *PLoS ONE*. 2012;7(9):e46575. PMID: PMC3460916
24. Xu C, Wang P, Liu Y, Zhang Y, Fan W, Upton MP, Lohavanichbutr P, Houck JD, Doody DR, Futran ND, Zhao LP, Schwartz SM, Chen C, Méndez E. Integrative genomics in combination with RNA interference identifies prognostic and functionally relevant gene targets for oral squamous cell carcinoma. *PLoS Genetics*. Jan 2013;9(1):e1003169. PMID: PMC3547824.
25. Lohavanichbutr P*, Méndez E*, Holsinger FC, Rue TC, Yuzheng Z, Houck JD, Upton MP, Futran ND, Schwartz SM, Wang P, Chen C. A 13-gene signature prognostic of HPV-negative oral cavity cancer: Discovery and external validation. (*Co-first authors). *Clinical Cancer Research*. Mar 2013;19(5):1197-03. PMID: PMC3593802.
26. Martins R, Parvathaneni U, Bauman JE, Sharma AK, Raez LE, Papagikos MA, Yunus F, Kurland B, Eaton K, Liao JJ, Méndez E, Futran N, Wang DX, Chai X, Wallace SG, Austin M, Schmidt R, Hayes DN. Cisplatin-radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: A randomized phase II trial. *Journal of Clinical Oncology*. Apr 2013;31(11):1415-21. PMID: 23460709.
27. Sharma A, Schwartz SM, Méndez E. Hospital volume is associated with survival but not multimodality therapy in medicare patients with advanced head and neck cancer. *Cancer*. May 2013 15;119(10):1845-52. PMID: 23456789.

28. Patel SA, Magnuson JS, Holsinger FC, Karni RJ, Richmon JD, Gross ND, Bhrany AD, Ferrell JK, Kennedy AA, Ford SE, **Méndez E**. Robotic surgery for primary head and neck squamous cell carcinoma of unknown site. *JAMA Otolaryngology-Head and Neck Surgery*. Nov 2013;139(11):1203-11. PMID: 24136446.
29. Bauman J, Austin M, Schmidt R, Kurland B, Vaezi A, Hayes DN, **Méndez E**, Parvathaneni U, Chai X, Sampath S, Martins RG. ERCC1 is a prognostic biomarker in locally advanced head & neck cancer: Results from a randomized, phase II trial. *British Journal of Cancer*. Oct 2013;109:2096-2105. PMCID: PMC3798971.
30. Zhang XC, XU C, Mitchell RM, Zhang B, Zhao D, Li Y, Huang X, Fan W, Wang H, Lerma LA, Upton MP, Hay A, **Méndez E***, Zhao LP*. Tumor evolution and intratumor heterogeneity of an oropharyngeal squamous cell carcinoma revealed by whole-genome sequencing. *Neoplasia*. Dec 2013;15(12):1371-8. (*co-corresponding authors). PMCID: PMC3884528.
31. Moser R, Xu C, Kao M, Annis J, Lerma LA, Schaupp C, Gurley K, Jang IS, Biktasova A, Yarbrough W, Margolin A, Grandori C, Kemp C*, **Méndez E***. Functional kinomics identifies candidate therapeutic targets in head and neck cancer. *Clinical Cancer Research*. Aug 2014;20(16):4274-88. (co-corresponding authors). PMCID: PMC4135446.
32. Mitchell RM, **Méndez E**, Schmitt NC, Bhrany AD, Futran ND. Antibiotic Prophylaxis in Head and Neck Patients Receiving Free Flap Reconstruction. *JAMA Otolaryngology-Head and Neck Surgery*. Dec 2015 141(12):1096-103. PMID: 25905902.
33. Chen C, Zhang Y, Loomis MM, Upton MP, Lohavanichbutr P, Houck JR, Doody DR, **Méndez E**, Futran N, Schwartz SM, Wang P. Genome-Wide Loss of Heterozygosity and DNA Copy Number Aberration in HPV-Negative Oral Squamous Cell Carcinoma and Their Associations with Disease-Specific Survival. *PLoS One*. Aug 2015; 10(8). PMCID: PMC4527746.
34. Baik F, Hansen S, Knoblauch SE, Sahetya D, Mitchell RM, Xu C, Parrish-Novak J, **Méndez E**. BLZ-100, a chlorotoxin-indocyanine green conjugate, identifies head and neck squamous cell carcinoma and high-risk oral dysplasia. *JAMA Otolaryngology-Head and Neck Surgery*. Apr 2016; 142(4):330-8. PMID: 2682902. PMCID: PMC4972605.
35. Sharma A, Patel S, Baik F, Mathison G, Pierce B, Khariwala S, Yueh B, Schwartz S, **Méndez E**. Oropharyngeal cancer patients treated with TORS have comparable survival and lower gastrostomy prevalence than matched chemoradiation patients. *JAMA Otolaryngology-Head and Neck Surgery*. In Press.
36. Rodriguez CP, Parvathaneni U, **Méndez E**, Martins RG. Salivary Gland Malignancies. *Hematology/Oncology Clinics of North America*. Dec 2015; 29(6):1145-57. PMID: 26568553
37. Gerhard D, Clemons P, Shamji A, Hon C, Wagner B, Schreiber S, Krasnitz A, Sordella R, Sander C, Lowe S, Powers S, Smith K, Aburi M, Iavarone A, Lasorella A, Silva J, Stockwell B, Califano A, Boehm J, Vazquez F, Weir B, Hahn W, Khuri, F, Moreno C, Johns M, Fu H, Nikolova O, **Méndez E**, Gadi V, Margolin A, Grandori C, Kemp C, Warren E, Riddell S, McIntosh M, Gevaert O, Kuo C, Ji H, Dhruv H, Finlay D, Kiefer J, Kim S, Vuori K, Berens M, Hangauer M, Boettcher M, Weissman J, Bivona T, Bandyopadhyay S, McManus M, McCormick F, Aksoy O, Simonds E, Zheng T, Chen J, An Z, Balmain A, Weiss W, Chen K, Liang H, Scott K, Mills G, Posner B, MacMillan J, Minna J, White M, Roth M, Jagu S, Mazerik J. Transforming Big Data into cancer-relevant insight: An initial, multi-tier approach to assess reproducibility and relevance. *Molecular Cancer*. Aug 2016;14(8):675-8. PMCID: PMC4987219.
38. Baik FM, Hansen S, Knoblauch SE, Sahetya D, Mitchell RM, Xu C, Olson JM, Parrish-Novak J, **Méndez E**. Fluorescence Identification of Head and Neck Squamous Cell Carcinoma and High-Risk Oral Dysplasia With BLZ-100, a Chlorotoxin-Indocyanine Green Conjugate. *Otolaryngology-Head and Neck Surgery*. Apr 2016;142(4):330-8. PMCID: PMC4972605.
39. Araki D, Redman MW, Martins R, Eaton K, Baik C, Chow L, Goulart B, Lee S, Santana-Davila R, Liao J, Parvathaneni U, Laramore G, Futran N, **Méndez E**, Bhrany A, Rodriguez CP. Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience. *Head & Neck*. Sep 2016;38(9):1318-23. PMID: 27061333.

40. Patel SA, Parvathaneni A, Parvathaneni U, Houlton JJ, Karni R, **Méndez E**. Post-operative Therapy Following Transoral Robotic Surgery for Unknown Primary Cancers of the Head and Neck. *JAMA Otolaryngology-Head and Neck Surgery*. **Under expedited review**
41. Kao M, Sidorova J, Green C, **Méndez E**. Strategies for targeted therapy in HNSCC using WEE1 inhibitor AZD1775. *JAMA Otolaryngology-Head and Neck Surgery*. **Under expedited review**

BOOK CHAPTERS

1. LaCorier, Holsinger C, **Méndez E**, Deschler D. Chapter 34: “Exam Under Anesthesia For the Patient With Cancer: Direct Laryngopharyngoscopy and Mucosal Tattooage.” In *Atlas of Head and Neck Surgery*. Eds: Cohen JI, Clayman GL. Philadelphia, PA: Elsevier Publishing
2. Schmitt NC, **Méndez E**: “Head and Neck Surgery.” In *Otolaryngology Surgical Instrument Guide*. Eds: Golub JS, Schmitt NC. San Diego, CA: Plural Publishing.
3. Rodriguez C, Parvathaneni U, **Méndez E**, Martins R: “Salivary Gland Malignancies.” In *Hematology/Oncology Clinics of North America*. Eds: Colevas A. Elsevier Publishing

ABSTRACTS

1. **Méndez E**, Kawanishi T, Clemens K, Siomi H, Soldan S, Calabresi P, Brady J, Jacobson S. Astrocyte-specific expression of human T-cell lymphotropic virus type I (HTLV-1) tax: Induction of tumor necrosis factor alpha and susceptibility to lysis by CD8+ HTLV-1-specific cytotoxic T-cells eighth international conference on human retrovirology: HTLV. Oral presentation, *International Retrovirology Association-HTLV and Related Viruses and Instituto Nacional de Cancer*. June 9-13, 1997. Rio de Janeiro, Brazil.
2. **Méndez E**, Farwell DG, Chen C. Differential genetic expression profile of oral squamous cell carcinomas. Poster presentation, *American Association for Cancer Research: “Oncogenomics: Dissecting Cancer through Genomic Research.”* Jan. 25-28, 2001. Tucson, AZ.
3. Cheng C, **Méndez E**, Chen C, Zhao LP. Regression-based statistical methods to analyze differentially expressed genes and its application to a study of oral cancer transcriptional profiles. Presented at *The 2nd Annual Northwest Microarray Conference*. Aug. 15-17, 2001. Seattle, WA.
4. **Méndez E**, Cheng C, Farwell DG, Agoff SN, Futran ND, Weymuller EA, Jr., Maronian N, Zhao LP, Chen C. Transcriptional expression profiles of oral squamous cell carcinomas. Oral presentation, *American Head and Neck Cancer Society 2002 Annual Meeting*. May 11-13, 2002. Boca Raton, FL.
5. Chen C, **Méndez E**, Cheng C, Farwell DG, Ricks S, Agoff SN, Futran ND, Weymuller EA, Jr., Maronian NC, Zhao LP. Transcriptional expression profiles of oral squamous cell carcinomas. Oral presentation, *The 6th Research Workshop on the Biology, Prevention, and Treatment of Head and Neck Cancer*. Oct. 9-13, 2002. McLean, VA.
6. Kuo WP, **Méndez E**, Chen C, Whipple M, Park PJ. Functional relationships between gene pairs in oral squamous cell carcinoma. *American Medical Informatics Association Meeting*. Nov., 2003. Washington DC.
7. Whipple ME, **Méndez E**, Farwell DG, Agoff SN, Chen CA. Genomic predictor of oral squamous cell carcinoma using principal component analysis. Oral presentation, *The American Laryngological, Rhinological and Otolological Society Western Section Meeting*. 2004. Scottsdale, AZ.
8. **Méndez E**, Fan WH, Agoff SN, Farwell DG, Zhao LP, Whipple M, Futran ND, Weymuller EA, Jr., Maronian N, Chen C. Genetic markers of metastasis for oral squamous cell carcinoma to the cervical lymph nodes. Oral

- presentation, “*Best of Basic Science Series,*” *The 6th International Conference on Head and Neck Cancer*. Aug. 7-11, 2004. Washington DC.
9. Houck J, Lohavanichbutr P, Doody D, **Méndez E**, Yueh B, Futran N, Schwartz S, Chen C. Promoter methylation status in putative tumor suppressor and cell adhesion-related genes in oral squamous cell carcinoma. *94th Annual American Head & Neck Society Meeting*. Aug. 17-20, 2006. Chicago, IL.
 10. **Méndez E**, Houck J, Doody D, Lohavanichbutr P, Fan W, Yueh B, Futran ND, Upton MP, Zhao LP, Schwartz SM, Chen C. A genetic expression profile associated with oral cancer identifies a high-risk group of oral cancer patients with poor survival. *AACR Annual Meeting*. April 12-16, 2008. San Diego, CA.
 11. Chen Y, Wang P, Xu C, Houck JR, Lohavanichbutr P, **Méndez E**, Futran ND, Yueh B, Schwartz SM, Zhao LP, Chen C. Genome-wide loss of heterozygosity, copy number variations and oral squamous cell carcinoma. *AACR Annual Meeting*. April 12-16, 2008. San Diego, CA.
 12. Chen C, **Méndez E**, Houck JR, Fan W, Lohavanichbutr P, Yueh B, Futran ND, Upton MP, Farwell DG, Schwartz SM, Zhao LP. Gene expression profiling identifies genes predictive of oral squamous cell carcinoma. *AACR Annual Meeting*. April 12-16, 2008. San Diego, CA. (Abstract)
 13. Lohavanichbutr P, Houck J, Fan W, Yueh B, **Méndez E**, Futran N, Doody DR, Upton MP, Farwell DG, Schwartz SM, Zhao LP, Chen C. Genome-wide gene expression profiles of HPV-positive and HPV-negative oropharyngeal cancer: Potential implications for treatment choices. *AACR Annual Meeting*. April 12-16, 2008. San Diego, CA.
 14. Houck J, Lohavanichbutr P, Doody DR, Futran N, **Méndez E**, Yueh B, Upton M, Schwartz SM, Chen C. Promoter hypermethylation and hypomethylation and oral squamous cell carcinoma. *7th International Conference on Head & Neck Cancer*. July 19-23, 2008. San Francisco, CA.
 15. **Méndez E**, Houck J, Doody DR, Lohavanichbutr P, Yueh B, Futran ND, Upton MP, Schwartz SM, Zhao L, Chen C. Gene expression profiling identifies a signature associated with oral cancer-specific survival. *7th International Conference on Head & Neck Cancer*. July 19-23, 2008. San Francisco, CA.
 16. Chang Xu, Yan Liu, Pei Wang, Melissa P. Upton, Wenhong Fan, Pawadee Lohavanichbutr, John R. Houck, David R. Doody, Neal D. Futran, Lue P. Zhao, Stephen M. Schwartz, Chu Chen, **Eduardo Méndez**. Association of genome-wide DNA copy number aberrations and gene expression in metastatic oral squamous cell carcinoma (OSCC). *AACR Annual Meeting*. April 18-22, 2009.
 17. Lohavanichbutr P, Houck J, Doody D, Fan W, **Méndez E**, Futran N, Upton M, Schwartz S, Chen C. Overexpression of miR-21 in oral squamous cell carcinoma & its correlation with the TGF-beta signaling pathway. *Combined Otolaryngology Spring Meetings*. May 29-31, 2009. Phoenix, AZ.
 18. Lohavanichbutr P, Houck J, Stott-Miller M, Doody DR, **Méndez E**, Futran N, Upton MP, Schwartz SM, Chen C. MicroRNA as a potential diagnostic marker for oral squamous cell carcinoma. *101st American Association for Cancer Research Annual Meeting*. April 17-21, 2010. Washington DC.
 19. Xu C, Liu Y, Wang P, Fan W, Rue TC, Upton MP, Houck JR, Lohavanichbutr P, Doody DR, Futran ND, Zhao LP, Schwartz SM, Chen C, **Méndez E**. Integrative analysis of DNA copy number and gene expression in metastatic tumor cells from oral squamous cell carcinoma for the identification of genes associated with disease-specific survival. *101st American Association for Cancer Research Annual Meeting*. April 17-21, 2010. Washington DC.
 20. **Méndez E**, Xu C, Liu Y, Fan W, Upton MP, Houck JR, Lohavanichbutr P, Doody DR, Futran ND, Zhao LP, Schwartz SM, Wang P, Chen C. DNA copy number-associated differential gene expression between tumor cells from metastatic lymph nodes vs. those from node-negative primary tumors in oral cancer. *American Head & Neck Society 2010 Annual Meeting*. April 28-29, 2010. Las Vegas, NV.
 21. LaPointe J, Upton MP, Doody DR, Houck J, Lohavanichbutr P, **Méndez E**, Futran N, Chen C. Histologic features of oral squamous cell carcinoma invasive front correlate with genetic markers of survival and/or metastasis. *United States & Canadian Academy of Pathology 100th Annual Meeting*. Feb 26-March 4, 2011. San Antonio, TX.

22. Serrano NA, Xu C, Lui Y, Wang P, Fan W, Upton MP, Houck JR, Lohavanichbutr P, Doody DR, Futran ND, Zhao LP, Kao M, Schwartz SM, Chen C, **Méndez E**. Association of DNA copy number and miRNA expression in OSCC. *2011 American Academy of Otolaryngology-Head and Neck Surgery Annual Meeting*. Sept. 9-14, 2011. San Francisco, CA.
23. Sharma A, **Méndez E**, Doody D, Houch J, Doody D, Lohavanichbutr P, Futran ND, Yueh B, Schwartz SM, Chen C. HPV+ oral cancer patients do not have better QOL trajectory. *2011 American Academy of Otolaryngology-Head and Neck Surgery Annual Meeting*. Sept. 9-14, 2011. San Francisco, CA.
24. Lamarre ED, Patel S, Sharma A, Futran ND, **Méndez E**. Retrospective review of transoral robotic surgery at the University of Washington. *The 8th International Conference on Head and Neck Cancer*. July 21-25, 2012. Toronto, Canada.
25. Sharma A, Schwartz SM, **Méndez E**. The effect of hospital volume and designated cancer center status on treatment and survival in patients advanced head and neck cancer. *The 8th International Conference on Head and Neck Cancer*. July 21-25, 2012. Toronto, Canada.
26. Kao M, Moser R, Xu C, Lerma LA, Annis J, Grandori C, Kemp CJ, **Méndez E**. Functional genomics approach to discover novel survival kinases in metastatic head and neck squamous cell carcinoma. *8th International Conference on Head and Neck Cancer*. July 21-25, 2012. Toronto, Canada.
27. Lerma LA, Anderson JC, Xu C, Kao M, Kyoung-Hee K, Annis J, Rohrback TD, Grandori C, Willey CD, **Méndez E**. Kinome profiling identifies novel therapeutic targets in p53-mutant, metastatic head and neck squamous cell carcinoma. *8th International Conference on Head and Neck Cancer*. July 21-25, 2012. Toronto, Canada.
28. Uppaluri R, Winkler AE, Sunwoo JB, Houck JR, Lohavanichbutr P, **Méndez E**, Schwartz SM, Chen C, Onken MD. Molecular analysis of tumor aggressiveness in a new mouse model of oral cancer. *8th International Conference on Head and Neck Cancer*. July 21-25, 2012. Toronto, Canada.
29. Patel SA, Magnuson JS, Holsinger FC, Karni RJ, Richmon JD, Gross ND, Bhrany AD, Ferrell JK, Kennedy AA, Ford SE, **Méndez E**. Role of robotic surgery for an unknown primary head & neck squamous cell carcinoma. *American Academy of Otolaryngology-Head and Neck Surgery Annual Meeting*. April 10-14, 2012. Orlando, FL.
30. Bresnahan B, He H, Alfonso-Cristancho R, **Méndez E**, Goulart B, Parvathaneni U, Kramer B, Anzai Y. Imaging and treatment patterns for privately-insured head and neck cancer patients in the United States. *American Roentgen Ray Society Annual Meeting*. May 4-9, 2014. San Diego, CA.
31. Nikolova O, Gönen M, Dienstmann R, Jang IS, Moser R, Cermelli S, Xu C, Mitchell RM, **Méndez E**, Grandori C, Kemp C, Friend S, Guinney J, Margolin A. Integrated computational cell-line modeling of drug sensitivity and high-throughput siRNA screening reveals novel molecular biomarkers for conventional chemotherapy. *American Association of Cancer Research, April 5-9th, 2014*. San Diego, CA.
32. Mitchell RM, Zhang XC, Xu C, Fan W, Zhao LP, **Méndez E**. Tumor evolution and intratumor heterogeneity of an oral squamous cell carcinoma revealed by whole genome and whole transcriptome sequencing. *Triological Society Combined Otolaryngology Spring Meetings*. May 14-18, 2014. Las Vegas, NV.
33. Baik FM, Xu C, **Méndez E**. Fluorescence detection of oral squamous cell carcinoma with indocyanine green-labeled chlorotoxin in an orthotopic xenograft model. *5th World Congress of the International Federation of Head and Neck Oncologic Societies and joint Annual Meeting of the American Head and Neck Society*. July 26-30, 2014. New York, NY.
34. Xu C, Mitchell RM, Jang IS, Moser R, Nikolova O, Hu Y, Dang K, Guinney J, Margolin A, Grandori C, Kemp C, and **Méndez E**. Genome scale RNAi screen of patient-derived tumor cell cultures identifies cisplatin sensitizers in head and neck squamous cell carcinoma. *5th World Congress of the International Federation of Head and Neck Oncologic Societies and joint Annual Meeting of the American Head and Neck Society*. July 26-30, 2014. New York, NY.
35. Li S, Ferris R, Holsinger FC, Weinstein G, Quon H, Mehra R, García J, Chung C, Gillison M, Wagner L, Ringash J, Lewin J, **Méndez E**, Ridge J, Richmon J, Magnuson JS, Bell RB, Smith R, Thomas G, and Burtness B. ECOG 3311 Trial of Transoral Endoscopic Head and Neck Surgery for Oropharynx Cancer: Implementation of a Novel Surgeon

Credentialing and Quality Assurance Process. *American Society of Clinical Oncology Annual Meeting*. June 3-7, 2016. Chicago, IL.

36. Xu C, Nikolova O, Jang I, Mitchell R, Zhang Y, Guinney J, Margolin A, Grandori C, Kemp C, **Méndez E**. Genome Scale RNAi Screen of Patient-Derived Tumor Primary Cells for the Identification of Therapeutic Targets and Chemo-Sensitizers in Head and Neck Squamous Cell Carcinoma (HNSCC). *AHNS 9th International Conference on Head and Neck Cancer*. July 16-20, 2016. Seattle, WA.
37. Kao M, Kehrli K, Green C, Sidorova J, **Méndez E**. Developing WEE1 Inhibitor as a Targeted Therapy to p53 Deficient Head and Neck Cancer. *AHNS 9th International Conference on Head and Neck Cancer*. July 16-20, 2016. Seattle, WA.
38. Green C, Kao M, de Leeuw C, Xu C, Park H, Moser R, Grandori C, Kemp C, **Méndez E**. Targeting G2/M Kinases as Synthetic Lethal Targets in p53 Deficient HNSCC. *AHNS 9th International Conference on Head and Neck Cancer*. July 16-20, 2016. Seattle, WA.
39. Patel S, Parvathaneni A, Futran N, Houlton J, **Méndez E**. Role of Margin Status in Trans-Oral Robotic Surgery for Head & Neck Squamous Cell Carcinoma. *AHNS 9th International Conference on Head and Neck Cancer*. July 16-20, 2016. Seattle, WA.
40. Patel S, Parvathaneni A, Parvathaneni U, Houlton J, Karni R, **Méndez E**. Post-operative Therapy Following Transoral Robotic Surgery for Unknown Primary Cancers of the Head and Neck. *AHNS 9th International Conference on Head and Neck Cancer*. July 16-20, 2016. Seattle, WA.

INVITED PRESENTATIONS, NATIONAL SYMPOSIA AND PROFESSORED PANELS

1. Use of Laser Capture Microdissection for Transcriptional Profiling Oral Squamous Cell Carcinoma. Pulmonary and Critical Care Medicine Research Group, University of Washington. November, 2003.
2. Gene Expression Profiling of Metastatic Oral Squamous Cell Carcinoma. Fred Hutchinson Cancer Research Center Genetic Epidemiology and Microarray Technology Affinity Group. December 2004.
3. Solid Tumor Oncology 2006: Targeted Approaches to Cancer Care CME. Seattle Cancer Care Alliance. September 28-29, 2006.
4. Genetic Markers of Disease Progression in Oral Squamous Cell Carcinoma. Guest Speaker, Department of Otolaryngology-Head and Neck Surgery, Pittsburgh, PA. October, 2006.
5. Free Tissue Transfer for Post-traumatic Craniofacial Defects. About Face: 2007, Madigan Army Medical Center. July, 2007.
6. Surgical Management of Bisphosphonate-associated Osteonecrosis of the Jaw. Jaw Osteonecrosis Related to Bisphosphonates CME/CDE Symposium. Seattle Cancer Care Alliance. April 4, 2008.
7. Update on Premalignant and Malignant Lesions of the Head, Neck, and Oral Cavity CDE. Course Faculty, University of Washington. October 24, 2008.
8. Advances in Head and Neck Cancer. Seattle Cancer Care Alliance, Wenatchee, WA. April 30, 2009.
9. Integrative Genomics Approach for Biomarker Discovery in Oral Squamous Cell Carcinoma. Grand Rounds, Clinical Research Division, Fred Hutchinson Cancer Research Center. September 14, 2009.
10. Advances in Head and Neck Surgery. Grand Rounds, Department of Radiation Oncology. November 12, 2009.
11. Integrative Genomics Approach for Biomarker Discovery in Oral Squamous Cell Carcinomas. Grand Rounds, Cancer Center, University of Texas. March 8, 2010.
12. TransOral Robotic-Assisted Surgery for Tumors of the Upper Aerodigestive Tract. Grand Rounds, University of Washington. October 19, 2010.

13. TransOral Robotic-Assisted Surgery for Tumors of the Upper Aerodigestive Tract. Fall Dinner Meeting, Northwest Academy of Otolaryngology. October 21, 2010.
14. Robotic-Assisted Surgery for Tumors of the Upper Aerodigestive Tract. Indiana University. April 11, 2011.
15. The Emerging Role of Robotic Surgery for the Treatment of Head and Neck Cancer. Visiting Professorship, UC Davis, University of California. July, 2011.
16. Robotic-Assisted Surgery for Treatment of Tumors of the Upper Aerodigestive Tract. Course Co-Director and Speaker, Pacific Northwest Head, Neck and Thyroid Symposium. April 1, 2011.
17. Minimally Invasive Approaches for Surgical Management for Tumor of the Upper Aerodigestive Tract. CME Featured Speaker, Seattle Cancer Care Alliance Network, Providence Alaska Medical Center. July 5, 2011.
18. The Emerging Role of Robotic Surgery for the Treatment of Head and Neck Cancer. Medical Oncology Grand Rounds, Seattle, WA. January 3, 2012.
19. Surgical Management for the Treatment of Early Stage Laryngeal Carcinoma. Head and Neck Resident Lecture Series, Department of Otolaryngology, University of Washington. January 4, 2012.
20. Transaxillary Robotic Thyroid Surgery – To Do or Not to Do? Pacific Northwest Head and Neck and Thyroid Cancer Symposium. April 6, 2012.
21. Robotic-Assisted Surgery for the Head and Neck. Course Faculty, Northwest Academy of Otolaryngology Winter Dinner. January 6-7, 2012.
22. Status of Organ Preservation in Head and Neck Cancer. Head and Neck Sea to Summit, Park City, UT. August 7-9, 2012.
23. Status of Organ Preservation in Head and Neck Cancer. CME Featured Speaker, Seattle Cancer Care Alliance Network, Mt Vernon, WA. October 3rd, 2012.
24. Status of Organ Preservation in Head and Neck Cancer. CME Featured Speaker, Seattle Cancer Care Alliance Network, Wenatchee, WA. March 13, 2013.
25. Evidence for Surgery: Will Management Decisions Change with the Use of Biomarkers in 2013? Expert Panel Speaker. Panel: *Evidence Based Management of Oral Cavity Cancer*. American Head and Neck Society Meeting at COSM, Orlando, FL. April 11, 2013.
26. Lower Lip Reconstruction. Third Annual Pacific Northwest Head and Neck Cancer Symposium: Update on Head and Neck Skin Cancers. Course Co-Director and Speaker, Seattle, WA. April 19th, 2013
27. Molecular Profiling of Head and Neck Cancers: Implications for Therapy. Grand Rounds, Radiation Oncology, University of Washington. May 22, 2013.
28. Molecular Profiling of Head and Neck Cancers: Implications for Therapy. Grand Rounds, Otolaryngology-Head and Neck Surgery, University of Maryland. August 19, 2013.
29. The Emerging Role of Robotic Surgery in the Management of Head and Neck Cancer. Sisson Symposium. Course Faculty, Vancouver, BC. September 30, 2013.
30. Molecular Profiling of Head and Neck Cancers: Implications for Therapy. Visiting Professorship, Otolaryngology-Head and Neck Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY. October 10, 2013.
31. Molecular Profiling of Head and Neck Cancers: Implications for Therapy. Grand Rounds, Otolaryngology-Head and Neck Surgery, Yale University. November 1, 2013.
32. A Decade of Head and Neck Cancer 'Omics': A Translational Initiative Towards Precision Oncology, Grand Rounds, Emory University. November 14, 2013.

33. A Decade of Head and Neck Cancer 'Omics': A Translational Initiative Towards Precision Oncology, Grand Rounds, Yale Cancer Center, Yale University. January 21, 2014.
34. Realizing the Promise of Personalized Medicine for Head and Neck Cancer: Will Management Decisions Change with the Use of Biomarkers in 2014? The 24th Annual Alumni Day Symposium, Rutgers Medical School. June 18, 2014.
35. The Emerging Role of Transoral Robotic Surgery for Treatment of Head and Neck Cancer. The 24th Annual Alumni Day Symposium, Rutgers Medical School. June 18, 2014
36. Transoral Robotic Surgery (TORS) for the Unknown Primary. 1st International TransOral Robot Surgery (TORS) Conference Presented by The Department of Otolaryngology-Head and Neck Surgery, The University of Pennsylvania Health System. July 24-25, 2014.
37. The Role of Transoral Robotic Surgery (TORS) for Head and Neck Squamous Cell Carcinoma: Diagnosis & Treatment of an Unknown Primary. The International Federation of Head and Neck Oncological Societies (IFHNOS) 5th World Congress in New York, in combination with The American Head and Neck Society (AHNS) New York, NY. July 26-30, 2014.
38. The Role of of Transoral Robotic Surgery (TORS) for HPV+ Head and Neck Squamous Cell Carcinoma. The HPV Head and Neck Cancer Epidemic: What You Need to Know Session. American Academy of Otolaryngology- Head and Neck Surgery, Orlando, FL. September 23, 2014.
39. The HPV+ Head and Neck Cancer Epidemic: What Your Spouse Needs to Know. 2015 Northwest Academy of Otolaryngology Winter Conference, Whistler, BC. January 17-19, 2015.
40. Targeted Fluorescence Imaging of Head and Neck Cancer: Toward Fluorescence-Guided Surgery. AHNS Translational Research Workshop on Transforming Patient Care Through Innovative Research, Boston, MA. April 21-22, 2015.
41. A Decade of Head and Neck Cancer 'Omics': A Translational Initiative Towards Precision Oncology. AHNS Translational Research Workshop on Transforming Patient Care Through Innovative Research, Boston, MA. April 21-22, 2015.
42. Functional Genomics Screening of Protein Kinases Identifies WEE1 as a Therapeutic Target in p53-Mutated Head and Neck Cancer. Systems Biology for Disease. Summer Course: Systems Biology of Disease, Seattle, WA. July 27-31, 2015.
43. Realizing the Promise of Precision Oncology Here at Home. Solid Tumor Translational Research 2015 Retreat, Seattle, WA. June 26, 2015.
44. The Role of TORS in the Management of the Unknown Primary Tumor. 3rd International TransOral Robotic Surgery (TORS) Conference, San Francisco, CA. July 14-15, 2016.
45. Pharynx/Larynx: "Reconstructive Options for Hypopharyngeal Tumors". 6th Annual Pacific Northwest Head and Neck Cancer Symposium. Advances in Reconstruction: Optimizing Form and Function, Seattle WA. July 15, 2016.
46. The Role of Transoral Robotic Surgery (TORS) for Treatment and Reconstruction in Head and Neck Cancer. 6th Annual Pacific Northwest Head and Neck Cancer Symposium: Advances in Reconstruction: Optimizing Form and Function, Seattle, WA. July 15, 2016.
47. Instructional Courses 3 - Biomarkers and Signature Therapeutics: Integrating into Clinical Practice. AHNS 9th International Conference on Head and Neck Cancer, Seattle, WA. July 16-20, 2016.
48. Targeted Therapeutics and Translational Research: Wee1 Targeting in p53-deficient HNSCC: Updates on our AZD1775 Neoadjuvant Phase I Trial. AHNS 9th International Conference on Head and Neck Cancer, Seattle, WA. July 16-20, 2016.
49. Actionable Therapy Based on TCGA: Data Towards Precision Oncology: Leveraging Public Datasets as a Pipeline for Target Discovery and Validation in Patient-Derived HNSCC Primary Cultures. AHNS 9th International Conference on Head and Neck Cancer, Seattle, WA. July 16-20, 2016.

50. TORS Course: Transoral Surgery for Head and Neck Pathology: A New Paradigm for the Management of the Unknown Primary. AHNS 9th International Conference on Head and Neck Cancer, Seattle, WA. July 16-20, 2016.

LANGUAGES

Fluent in English and Spanish